ClinicalTrials.gg
RecruitingNCT06430684SGLT2I-IN-KIDSUpdated Aug 19, 2026

Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease

An Early Phase 1 interventional study of Empagliflozin 10 MG in Chronic Kidney Diseases and Pediatric Kidney Disease, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago. Recruiting at 1 site in United States. Open to participants aged 12 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Ann & Robert H Lurie Children's Hospital of Chicago · Early Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
12 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing empagliflozin in Renal Insufficiency, Chronic — 6 open to participants now, 7 under way, 1 of them phase 3. empagliflozin · Renal Insufficiency, Chronic.

Planned enrollment
15th of 20
40 · median 77
Started
2024
with 4 others
Phase 1
2 of 20
1 open now
Registered
13th of 20
by date
Lead sponsor
1 of 20
Ann & Robert H Lurie Children's Hospital of Chicago

Among the 20 studies testing empagliflozin in Renal Insufficiency, Chronic, this one is the 15th largest by planned enrollment, is one of 5 that started in 2024, is one of 2 in phase 1, and was the 13th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

6 of the 20 studies testing empagliflozin in Renal Insufficiency, Chronic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 12 Years to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing empagliflozin in Renal Insufficiency, Chronic, or all of them as a file.
02

Study summary

The goal of this study is to learn if a clinical trial of sodium-glucose co-transporter 2 inhibitors (SGLT2i) is possible in youth with chronic kidney disease (CKD). The investigators also plan to explore whether treatment with SGLT2i (Empagliflozin) helps improve risk factors for worsening kidney and heart disease. The main questions are:

  1. Is enrolling 40 youth with CKD into a clinical trial of empagliflozin feasible (ie achievable)?
  2. Does taking empagliflozin for 3 months result in positive changes in blood, urine, and heart function tests?

Participants will be randomly selected (like flipping a coin) to either receive empagliflozin or not start treatment with empagliflozin and remain on their usual care.

Study Procedures Include

  • For participants randomly selected for treatment, take empagliflozin once daily for 3 months
  • Phone calls with researchers every 2 weeks for check-ins
  • For participants taking empagliflozin, clinic visits 4 and 8 weeks after starting for check-ups and tests
  • All study participants will have clinic visits at the beginning and end (3 months) where researchers will collect information about their health and perform tests
03

Conditions studied

  • Chronic Kidney Diseases
  • Pediatric Kidney Disease

Keywords

  • Sodium Glucose Co-Transporter 2 Inhibitor
  • SGLT2i
  • Pediatric CKD
  • Feasibility Study
  • Clinical Trial
04

Who can participate

Ages eligible
12 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Stage 3-4 CKD; estimated using CKiD U25-creatinine equation 20-60mL/min/1.73m2

Exclusion criteria

Exclusion Criteria:

  • Heart Disease
  • Diabetes
  • Pregnancy
  • Recipient of solid organ transplant
  • history of chemotherapy or stem cell transplant
  • moderate to severe persistent asthma
  • liver disease
  • class 2 or greater obesity
  • inability to follow study procedures due to cognitive impairment
  • obstructive uropathy or requirement for intermittent urinary catheterization
  • systolic blood pressure \<100mgHg
  • orthostatic hypotension
  • current use of an SGLT2i
  • anticipated need for titration of anti-hypertensives within 3 months
  • active use of any medications
  • lack of clearance by primary nephrologist for participation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Treatment

    Empagliflozin 10mg daily for 3 months (n=20)

    Drug: Empagliflozin 10 MG

  • No intervention
    Standard of Care

    Participants will not take empagliflozin (n=20)

Interventions

  • Empagliflozin is a sodium glucose co-transporter 2 inhibitor (SGLT2i) that is approved for the treatment of chronic kidney disease (CKD) in persons aged 18 years or older

06

What researchers measure

Primary outcomes

  1. Percentage of participants who complete all study procedures

    Compared to the number recruited, how many participants complete the study

    Time frame: 4 years

Secondary outcomes

  1. Systolic Blood Pressure

    In-clinic systolic blood pressure

    Time frame: 3 months

  2. Serum N-terminal pro-brain natruetic peptide (NT-proBNP)

    Time frame: 3 months

  3. Urine Albumin to Creatinine Ratio (UACr)

    Time frame: 3 months

  4. Left Atrial Reservoir Strain

    Measuring using echocardiography

    Time frame: 3 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Sep 2026, 24 months after the start.

Of 109 phase 1 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 27. This study's planned 24 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2024
First posted
May 28, 2024
StartActual
Aug 23, 2024
Primary completionEst.
Sep 1, 2026
CompletionEst.
Nov 1, 2026
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06430684
Responsible party
Sponsor
First posted
May 28, 2024
Start date
Aug 23, 2024
Primary completion
Sep 1, 2026 (estimated)
Completion
Nov 1, 2026 (estimated)
Last update
Aug 19, 2026

Study contacts

Alexander J Kula, MD, MHS
Contact
alexkula@luriechildrens.org
312-227-6160

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empagliflozin

Start the discussion